Allograft Versus Demineralized Bone Matrix in Instrumented and Noninstrumented Lumbar Fusion: A Systematic Review

Zorica Buser, PhD1, Darrel S. Brodke, MD2, Jim A. Youssef, MD3, Elke Rometsch, MSc4, Jong-Beom Park, MD5, S. Tim Yoon, MD, PhD6, Jeffrey C. Wang, MD1, and Hans-Joerg Meisel, MD, PhD7

Abstract

Study Design: Systematic review.

Objectives: The aim was to determine the fusion efficacy of allograft and demineralized bone matrix (DBM) in lumbar instrumented and noninstrumented fusion procedures for degenerative lumbar disorders.

Methods: A literature search was conducted using the PubMed and Cochrane databases. To be considered, publications had to meet 4 criteria: patients were treated for a degenerative lumbar disorder, a minimum group size of 10 patients, use of allograft or DBM, and at least a 2-year follow-up. Data on the study population, follow-up time, surgery type, grafting material, fusion rates, and its definition were collected.

Results: The search yielded 692 citations with 17 studies meeting the criteria including 4 retrospective and 13 prospective studies. Six studies used DBM and 11 employed allograft alone or in the combination with autograft. For the allograft, fusion rates ranged from 58% to 68% for noninstrumented and from 68% to 98% for instrumented procedures. For DBM, fusion rates were 83% for noninstrumented and between 60% and 100% for instrumented lumbar fusion procedures.

Conclusions: Both allograft and DBM appeared to provide similar fusion rates in instrumented fusions. On the other hand, in noninstrumented procedures DBM was superior. However, a large variation in the type of surgery, outcomes collection, lack of control groups, and follow-up time prevented any significant conclusions. Thus, studies comparing the performance of allograft and DBM to adequate controls in large, well-defined patient populations and with a sufficient follow-up time are needed to establish the efficacy of these materials as adjuncts to fusion.

Keywords: systematic review, lumbar spine, spinal fusion, allograft, demineralized bone matrix, autograft

Introduction

Lumbar spine fusion with and without instrumentation is frequently a treatment of choice for various spinal pathologies. Several studies have demonstrated an increase in the number of cases and associated costs in the past few decades.1-3 Various factors including surgical technique, primary or revision surgery, use of instrumentation, grafting materials, and patient comorbidities have an impact on fusion success. For instance, deleterious effects of cigarette smoking on spinal fusion have been highlighted in several studies.5-6 Graft materials play a crucial role in bone remodeling, and the adequate choice is dependent on patient’s condition as well as the surgical approach. Ideally, the graft material should be osteoconductive.

1 University of Southern California, Los Angeles, CA, USA
2 University of Utah, Salt Lake City, UT, USA
3 Spine Colorado, Durango, CO, USA
4 AO Foundation, Dubendorf, Switzerland
5 Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Uijeongbu, Korea
6 Emory University, Atlanta, GA, USA
7 Bergmannstrost Hospital, Halle, Germany

Corresponding Author:
Zorica Buser, Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, 1450 Biggy Street, NRT-2509N, Los Angeles, CA 90033, USA.
Email: zbuser@usc.edu

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License (http://www.creativecommons.org/licenses/by-nc-nd/4.0) which permits non-commercial use, reproduction and distribution of the work as published without adaptation or alteration, without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
osteoinductive, and osteogenic. Autologous iliac crest bone graft (ICBG) represents the only stand-alone graft with all 3 components needed for fusion. Studies have shown that ICBG performed better in single- and 2-level fusions than in 3 or more level procedures. Additionally, studies have shown that the fusion rates with ICBG are often lower in noninstrumented than in instrumented lumbar procedures. While ICBG has all 3 desired graft properties, several drawbacks including donor comorbidities, limited supply, and various complications have been noted.

As a result, the use of alternative materials such as allograft, demineralized bone matrix (DBM), synthetic materials (calcium sulfates, calcium phosphates, or hydroxyapatite), growth factors, and cell- or platelet-based therapies has greatly increased. Each of these graft materials has certain pros and cons that will guide patient selection. Allograft is readily available in large amounts and does not carry ICBG-related complications, in particular the harvest morbidity. During preparation, allografts are depleted of cells and growth factors and primarily provide osteoconduction with minor osteoinductivity. Its main disadvantages are immunogenicity and disease transmission. Based on the preparation procedure, allografts can be divided into 3 groups: fresh-frozen, freeze-dried, and DBM. Fresh-frozen allografts provide the highest mechanical stability, but at the same time they carry the highest risk of disease transmission. On the other hand, DBM has certain osteoinductive capabilities in addition to osteoconduction. However, studies have shown a large lot-to-lot variability. Various studies have looked at the use of allograft in lumbar spine in combination with ICBG or as a stand-alone graft. In posterolateral instrumented fusion, An et al reported no fusion with freeze-dried allograft, while Gibson et al found similar outcomes and revision rates at 6-year follow-up. Freeze-dried allografts in combination with autograft bone have been also used in deformity corrections, achieving over 90% fusion rates. At the same time several studies have looked at the DBM fusion potential in lumbar spine. Both Vaccaro et al and Cammisa et al reported similar fusion rates between DBM mixed with bone marrow aspirate or ICBG and ICBG alone. Despite the large number of clinical studies utilizing those graft materials, the existing reviews are often narrative rather than systematic, or the level of evidence is limited due to a small sample size, short follow-up times, lack of appropriate controls, or incomplete outcome information.

The purpose of this systematic review was to determine the fusion efficacy of allograft and DBM in lumbar instrumented and noninstrumented fusion procedures for degenerative lumbar disorders.

Materials and Methods

Search Strategy

A clinical epidemiologist performed a literature search using PubMed and 5 databases of the Cochrane Library in November 2013 and January 2014, respectively (Figure 1). Since the employed terminology is extremely diverse, the search strings were kept general to avert the risk of missing eligible publications. In order to be included in the review, allograft bone and DBM had to be used in fusion procedures for degenerative conditions of the lumbar spine. Any type of allograft bone or DBM was eligible for inclusion in the review as long as it was not used in combination with freshly harvested ICBG. The reason for this exclusion was that (1) if ICBG autograft was part of the graft, it would remain unclear whether the effect on fusion stemmed from the autograft or the alternative material, and (2) the goal of the review was to evaluate the potential of allograft and DBM as substitutes for ICBG.

Study Selection

Titles and abstracts of the initial matches were independently screened by 2 reviewers to identify eligible original publications. The initial search included original articles and articles with a focus on health economic aspects. When the title or the abstract were not sufficient to determine the eligibility, the full text was used. Whenever the 2 reviewers had a disagreement concerning the eligibility, a third reviewer decided.

Figure 1. PRISMA 2009 flow diagram. From Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med. 2009;6(6):e1000097. doi:10.1371/journal.pmed1000097.
Inclusion and Exclusion Criteria

Original publications were included if the following inclusion criteria were met:

1. **Population:** Adult patients being diagnosed with one of the following degenerative lumbar spine conditions: stenosis, radiculopathy, back pain, neurogenic claudication, degenerative spondylolisthesis, or lumbar adult degenerative deformity. The minimum group size was set at 10 patients. In studies where only one of the included groups met our eligibility criteria, only that group was analyzed.

2. **Intervention:** Patients had to undergo posterolateral or anterior fusion regardless of employment of cages and/or instrumentation.

3. **Comparison group:** Studies comparing allograft or DBM to autograft were included and results are presented for both intervention and control groups. Noncomparative studies were also included. When a comparison group was another graft material, the results of these studies were analyzed as if they were stand-alone results of a noncomparative study.

4. **Outcomes/time frame:** To be included studies had to have a minimum follow-up time of 2 years (mean) and had to contain radiological assessment of fusion.

Original publications were excluded if any of the following criteria applied:

1. **Population:** The majority of study patients suffered from nondegenerative diseases, for example, isthmic spondylolisthesis or idiopathic scoliosis.

2. **Intervention:** Revision surgery or the allograft or DBM was used to supplement ICBG.

3. **Time frame:** The publication date was before 1993.

Data Extraction

Information on study population, follow-up time, intervention (type of surgery and allograft used), fusion success, and its definition were collected. A standardized data extraction form was used. Any study characteristics that could have led to bias, for example, details about lost to follow-up or potential conflict of interest, were also captured.

Data Analysis

Due to the high variability among studies with regard to study focus, procedural type, definition of fusion, as well as the indication for surgery, all analysis were done on an individual level.

Results

A total of 692 potentially eligible original articles were identified (Figure 1). From those, 41 articles were retrieved for full-text evaluation and 14 were deemed appropriate for inclusion. Additionally, the full text of 16 review and health economic articles was screened for further eligible references and another 3 articles were included in the review. Subsequently, all eligible articles were screened for overlapping patient populations. Since there was no population overlap, all 17 articles were included in this review. No randomized controlled trial (RCT) comparing allograft or DBM to autograft met the eligibility criteria (Table 1).

Allograft

Eight prospective and 3 retrospective studies comparing allograft to autograft in posterior and anterior fusion with and without instrumentation were included. Only 5 out of 11 studies had groups with allograft alone. In the prospective study done by Andersen et al, 94 patients underwent instrumented (54.3%) or noninstrumented (45.7%) posterior lumbar fusion (PLF) procedures with fresh frozen femoral head allograft. At 12 and 24 months, a fusion rate of 68% for noninstrumented and 81% for instrumented fusion was reported (Tables 2 and 3). Additional 3 prospective studies on PLF and posterior lumbar interbody fusion (PLIF) enrolled 16 to 89 patients and graft material included autograft mixed with various forms of allograft (freeze-dried, machined, or cortical). In all 3 studies patients underwent instrumented procedures, resulting in fusion rates between 91.6% and 98% at 24 months. For anterior fusion procedures 2 retrospective and 3 prospective studies looked at the use of allograft in instrumented and noninstrumented fusion. Four out of 5 studies used structural allograft alone, with 2 studies using fibular and 2 femoral bone graft. In a case-control study done by Fauldez et al, the type of structural allograft used for anterior interbody fusion included tricortical iliac crest allograft in 41 patients (59.7%), milled femoral ring in 12 (17.9%), patella allograft alone in 11 (16.4%), and a combination of patella allograft and iliac crest allograft in 4 patients (6%). Two instrumented studies reported 82% fusion rates at 24 and 33 months, similar pseudarthrosis rates (13%), and significant improvements in the clinical outcomes. On the other hand, in the 3 noninstrumented anterior lumbar interbody fusion (ALIF) studies fusion rates were lower 58% to 66% and one study reported that 85% of the cases had graft subsidence. Although the fusion rates were lower than in instrumented studies, all 3 studies reported improvement in the clinical outcomes and return to work.

Three studies reported on the use of allograft in transforaminal lumbar interbody fusion (TLIF) procedures. Fauldez et al used a boomerang-shaped allograft spacer in 2 slightly different designs with 61.5% of the patients receiving a semilunar femoral ring graft and the other 38.5% having a split femoral ring allograft. At 33 months, the authors reported 77% fusion rates and improvement in the Short Form-36 (SF-36) score (Tables 2 and 3). Two additional nonrandomized studies utilizing TLIF with combination of local autograft and structural allograft were included in this review. The studies enrolled
| Author, Year | Sample Size | Follow-up (FU) Time | Indication | Levels (Number, Location) | Intervention | Fusion Rate | Reoperations |
|--------------|-------------|---------------------|------------|---------------------------|--------------|------------|--------------|
| PLF, structural allograft, instrumented and noninstrumented Andersen, 2009 | 51 noninstrumented; 43 instrumented | 4.3 years | “Spinal stenosis surgery where fusion was deemed necessary due to instability or the need for extensive decompression, or a high degree of back pain.” | I level 18 (35.3%); 2 levels 19 (37.3%); 3 levels 12 (23.5%); 4 and 5 levels 2 (3.9%) | PLF with fresh-frozen allograft (femoral head) | 68% at 12 and 24 months | Instrumented: 9/43 (20.9%), of these 4 were hardware removals due to loosening Noninstrumented: 6/51 (1.18%) |
| PLIF, allograft chips, instrumented Ploumis, 2010 | 16 (only allograft group considered) | 2 years | Degenerative lumbar scoliosis and spinal stenosis | “Up to 3 levels from L1-S1” | Instrumented PLF with allograft (freeze-dried cancellous chips) with local autograft | 93.7% at 24 months | No reoperations |
| PLIF, structural allograft, instrumented Arnold, 2009 | 89 | Up to 24 months | Disc failure or prolapse 53 (73.6%); Osteophytic spondylolisthesis 21 (29.2%); Facet hypertrophy osteoarthritis 24 (33.3%); Congenital spinal stenosis 2 (2.8%); Spondylolisthesis 10 (13.9%); Spondylolisthesis, pars defect 16 (22.2%); Spondylolisthesis, degenerative 8 (11.1%); Degenerative scoliosis 3 (4.2%); Trauma-induced instability 3 (4.2%) | I level: 52 patients (72.2%); 2 levels: 20 patients (27.8%) | Instrumented PLF (without cage), machined allograft PLIF spacers. Autograft with or without allograft extender was placed around and between PLIF spacers (surgeon's discretion) | 98% at 12 and 24 months | 3 Reoperations: 1 Repositioning of bone grafts because of posterior migration at 2 months 1 Cephalad extension of fusion plus decompression caused by stenosis above index level at 42 months 1 Repair of pseudomeningocele |
| Kakiuchi, 1998 | 71 patients presented as 2 groups: ≤50 years: 33 patients ≥60 years: 38 patients | 41 months | ≤50 years group: Disc herniation or post-discectomy failed back: 38 (53.5%); ≥60 years group: Degenerative spondylolisthesis: 33 (46.5%) | L3-4: 4 (6.5%); L4-5: 46 (64.8%); L5-S1: 19 (26.8%) | I-level PLIF with pedicle screws and hooks and rods, with or without any internal fixation Structural cortical bone allograft with cancellous bone autograft | 91.6% at 24 months | No reoperations |
| ALIF + posterior instrumentation, structural allograft, instrumented Faundez, 2009 (retrospective) | 65 ALIF with posterior fusion (presented here) 68 TLIF, transforminal lumbar interbody fusion (presented below) | Radiological: 33 months | Primary diagnosis of symptomatic disc degeneration (SDD) at 1 or 2 levels | I level: 21% 2 levels: 79% | ALIF combined with rods or translaminar facet screws (no cage). Posteriorly mix of morcellized allograft and local autograft | 82% at 33 months | Revision surgery for pseudarthrosis 9 (13.2%) patients Pseudarthrosis documented and patients considered for possible future revision because of symptoms: 3 (4.4%) patients |

(continued)
| Author, Year | Sample Size | Follow-up (FU) Time | Indication | Levels (Number, Location) | Intervention | Fusion Rate | Reoperations |
|--------------|-------------|---------------------|------------|--------------------------|-------------|------------|-------------|
| Slosar, 2007 (prospective) | 30 (only allograft group considered) | 24 months | Predominant low back pain refractory to nonsurgical treatment, painful DDD (L3-S1), grade I-II spondylolisthesis, degenerative scoliosis | 1 level: 30% 2 levels: 50% 3 levels: 20% | Instrumented ALIF with structural allograft (femoral ring) with additional chips in its middle | Grade I (solid fusion): 82% Grade II (bridging bone): 7% Grade III (not fused): 11% at 24 months | 4 patients (13%) reoperated for pseudarthrosis and 1 pending |
| Faundez, 2009 (retrospective) | 68 TLIF (presented here) 65 ALIF with posterior fusion (presented above) | Radiological 33 months | Primary diagnosis of symptomatic disc degeneration (DDD) at 1 or 2 levels | TLIF: 1 level: 5% 2 levels: 49% No location information | Instrumented TLIF with allograft spacer and local autograft behind the allograft spacer | 77% at 33 months | Revision surgery for pseudarthrosis: 12 (18.5%) patients Pseudarthrosis documented and patients considered for possible future revision because of symptoms: 3 (4.6%) patients |
| Kim, 2011 (retrospective) | 56 | 32.4 months | Recurred disc herniation: 5 (8.9%) Degenerative spondylolisthesis: 22 (39.3%) Isthmic spondylolisthesis: 18 (32.1%) Foraminal stenosis: 11 (19.6%) Primary diagnosis of symptomatic disc degeneration (SDD) at 1 or 2 levels | TLIF: 1 level: 9 (37.5%) 2 levels: 12 (50%) 3 levels: 2 (8.35%) 4 levels: 1 (4.15%) Majority: L4-S and L5-S | TLIF with Capston cage and instrumentation. Local autograft and allobone | Grade I: 73.2% Grade II: 23.2% at 32.4 months | None mentioned |
| Houten, 2006 (prospective) | 33 (independent radiological review in 23) | Clinical 37 months Radiological 11 months | Degenerative disease: 22 (91.6%) Isthmic spondylolisthesis: 8 (24%) Recurrent disc herniation: 14 (42%) DDD: 11 (33%) | L3-L4: 2 (6.1%) L4-L5: 16 (48.5%) LS-S1: 14 (42.4%) L4-S1: 1 (3.0%) | Instrumented TLIF with structural allograft and local autograft | 100% at 11 months | 3 patients with hardware removals after fusion mass had consolidated |
| Wiesel 1993 (Only lumbar group considered): 24 | 24 months | Degenitive disease: 22 (91.6%) Lumbar fracture: 1 (4.2%) Thoracolumbar kyphosis: 1 (4.2%) | Only 1 level fusions L3-4: 2 (6.25%) L4-5: 14 (43.75%) L5-S1: 16 (50.00%) | ALIF with fibular allograft | ALIF with fibular allograft: 60% ICBG PLF + pedicle screw: 69% ICBG PLF + facet screw: 50% ICBG ALIF w BAK + facet fusion: 88% at 4.2 years | No reoperations |
| Vamanji, 1998 (prospective) | Allograft group: 11 Control groups (all ICBG) PLF + pedicle screw: 13 PLF + facet screw: 16 ALIF w BAK cage: 16 | 4.2 years | Internal disc disruption | ALIF + allograft (N = 11) 1-level: 11 (100%) ICBG PLF + pedicle screw (N = 13): 1 level: 4 (30.8%) 2 levels: 7 (53.8%) 3 levels: 2 (15.4%) ICBG PLF + facet screw (N = 16) 1 level: 9 (56.25%) 2 levels: 7 (43.75%) ICBG ALIF w BAK (N = 16) 1 level: 7 (43.75%) 2 levels: 9 (56.25%) | Allograft group: ALIF with fibula allograft Various ICBG control groups (none of them stand-alone ICBG ALIF): ICBG PLF + pedicle screw ICBG PLF + facet screw ICBG ALIF w BAK | No reoperations |
| Kumar, 1993 (retrospective) | 32 | 24-48 month | Patients who underwent single-level anterior lumbar fusions | Only 1 level fusions L3-4: 2 (6.25%) L4-5: 14 (43.75%) L5-S1: 16 (50.00%) | ALIF with femoral strut allograft | Arthrodesis: 66% Functional arthrodesis: 22% Nonunion: 12% at 24 months | None reported |
| Epstein NE, 2008 (prospective) | 75 | Clinical 33 years Radiological 1 year | Patients undergoing multilevel lumbar laminectomies and noninstrumented fusions using lamina autograft and DBM. 5 patients w/ previous lumbar surgeries, of these 3 with multiple previous lumbar surgeries | Patients underwent average 4.9 level lumbar laminectomies and 2.0 level noninstrumented posterolateral lumbar fusions | PLF with DBM osteofit without cage or instrumentation | 82.7% at 12 months | 2 secondary interventions: 1 postoperative seroma; 1 secondary instrumented 1-year postoperatively |
| Author, Year         | Sample Size | Follow-up (FU) Time | Indication                                                                 | Levels (Number, Location)                                                                 | Intervention                                           | Fusion Rate                                                                 | Reoperations                                                                 |
|---------------------|-------------|---------------------|----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Epstein NA and JA, 2007 | 140 patients (95 one level, 45 two levels) | Clinical: 3.4 years Radiological: up to 12 months until fusion was documented | Patients undergoing multilevel lumbar laminectomies and instrumented fusions using lamina autograft and DBM | 1-level fusions: average 3.7 level lumbar laminectomies/patient with fusion in: L2-L4 0 L3-L4 0 L4-L5 0 L5-S1 0 L4-S1 0 | PLF with DBM Osteofil without cage but with instrumentation, with lamina autograft | PLF: 1-level fusions: 92.6% (2.1%): On 2D-CT; 97.9% (4.4%): On dynamic X-ray | 1-level fusion: 2 (2.1%); 2-level fusion: 2 (4.4%) |
| Kang, 2012          | 46 (randomized 2:1 DBM: 30 ICBG: 16) | 2 years             | Spinal stenosis with degenerative spondylolisthesis                     | DBM: 39 (69.6%); Deg disk disease 25 (44.6%); Segmental instability 39 (69.6%); Pseudoarthrosis 17 (30.4%); Postlamination pain 31 (55.4%); Spondylolisthesis 8 (10.7%); Spinal stenosis 6 (10.7%); Other 4 (7.1%); Control: Disk herniation 27 (51.9%); Deg disk disease 24 (46.2%); Segmental instability 37 (71.2%); Pseudoarthrosis 9 (17.3%); Postlamination pain 26 (50.0%); Spondylolisthesis 15 (28.9%); Spinal stenosis 11 (21.2%); Other 3 (5.8%) | Levels fused: DBM: 1 level 19 (33.9%); 2 levels 33 (58.9%); 3 levels 4 (7.1%); Control: 1 level 21 (40.4%); 2 levels 20 (38.5%); 3 levels 11 (21.2%); (location not documented) | DBM group: 86% (28 patients); ICBG group: 92% (13 patients) at 2 years | No reoperations |
| Sassard, 2000        | DBM group: 56 | 2 years             | Disk herniation 39 (69.6%); Deg disk disease 25 (44.6%); Segmental instability 39 (69.6%); Pseudoarthrosis 17 (30.4%); Postlamination pain 31 (55.4%); Spondylolisthesis 8 (10.7%); Spinal stenosis 6 (10.7%); Other 4 (7.1%); Control: Disk herniation 27 (51.9%); Deg disk disease 24 (46.2%); Segmental instability 37 (71.2%); Pseudoarthrosis 9 (17.3%); Postlamination pain 26 (50.0%); Spondylolisthesis 15 (28.9%); Spinal stenosis 11 (21.2%); Other 3 (5.8%) | PLF or PLIF with DBM Grafton without cage but with instrumentation | PLF: 60% Control 56% at final FU (24-month radiographs used for final analysis, earlier radiographs used for imputation in case of missing value) | None reported |
| Author, Year | Sample Size | Follow-up (FU) Time | Indication | Levels (Number, Location) | Intervention | Fusion Rate | Reoperations |
|-------------|-------------|---------------------|------------|---------------------------|--------------|-------------|--------------|
| TLF DBM, instrumented | Park, 2011 | 66 | 2 years | Spondylolytic spondylolisthesis: 23 (34.85%) (Meyering Grade 1, Grade 2): (12, 11) (18.2%; 16.65%) Degenerative spondylolisthesis: 24 (36.3%) (Meyering Grade 1, Grade 2): (22, 2) (33.35%; 3%) Degenerative lumbar instability*: 19 (28.8%) | L3–4: 5 (7.6%) L4–5: 40 (60.6%) L5–S1: 21 (31.8%) | Instrumented TLF with DBM (OsteofillRT) + local autograft Grade 1 (definitely solid): 50% Grade 2 (possibly solid): 27.3% Grade 3 (probably not solid): 3% Grade 4 (definitely not solid): 19.7% at 2 years | No reoperations |
| ALIF and TLF with structural allograft and DBM, instrumented | Vaidya, 2007 | 11 ALIF in 16 levels 18 TLF in 25 levels | 24 months | Revision surgery 13 Discogenic pain 7 Adult scoliosis 5 Spondylolisthesis 4 | ND | Instrumented ALIF and TLF with structural allograft and DBM (no DBM brand information available) 100% at 24 months | Reoperations in 4 patients (all scoliosis): 1 postoperative infection; 3 iliac screw removals for buttock pin |

*Segmental instability defined as ≥4 mm of translation or ≥10° of angular motion on preoperative flexion and extension radiographs.

---

Abbreviations: PLF, posterior lumbar fusion; PLIF, posterior lumbar interbody fusion; ALIF, anterior lumbar interbody fusion; DDD, degenerative disc disease; CT, computed tomography; ICBG, iliac crest bone graft; TLF, transforaminal lumbar interbody fusion.
Table 2. Definition of Fusion and Fusion Success.

| Author, Year | Fusion Rate                  | Definition of Fusion                                                                 |
|--------------|------------------------------|-------------------------------------------------------------------------------------|
| Andersen, 2009 | Instrumented: 81% at 12 and 24 months | Continuous intertransverse bony bridge had a minimum of one of the two sides indicating a fusion at that level. "Fusion" indicated this quality of fusion at all intended levels, "doubtful fusion" indicated suboptimal quality at one or more levels including fusion mass hidden behind the instrumentation, and "nonunion" indicated definite lack of fusion at one or more of the intended levels. If the fusion was doubtful in any way, the case was excluded from classification as "fused." |
| Ploumis, 2010 | 93.7% at 24 months | Presence of bridging bone between the transverse processes and measured translation and angulation on dynamic radiographs using digital calipers. In addition to bridging bone ≤ 5° of angular motion and ≤ 2 mm of translation were required to classify the cases as successfully fused, as per the definition of successful fusion provided by the FDA for use in clinical trials involving investigational devices to attain spinal fusion. |
| Arnold, 2009 | 98% at 12 and 24 months | For two-level fusion to be deemed successful, both levels had to meet the fusion criteria. Fusion was defined as evidence of bilateral continuous bridging of trabecular bone as well as less than 3 mm of translation and less than 5° of angular motion on lateral flexion-extension radiographs. CT scans were assessed for continuous bone formation throughout the length of the fusion bed. |
| Kakiuchi, 1998 | 91.6% at 24 months | For the final 24-month fusion status analysis, the subjects' radiological results were assessed as follows. Included in the final analysis were all subjects who reached the 12-month FU time point. If a subject had a radiograph and/or a CT scan that was assessed by the independent radiologist as "fused" at month 12 or at month 24 (when applicable), then the subject was classified as "fused" in the final analysis. If all the radiographs or CT scans obtained at months 12 and 24 were assessed as "not fused" and/or "indeterminate," then the subject was classified as "not fused" in the final analysis. Radiographical: preoperatively and immediately after surgery and at 6 weeks, 3, 6, 12, and 24 months postoperatively. Flexion-extension radiographs and computed tomographic (CT) scans (high-resolution axial, sagittal, and coronal reformattin) were obtained at 12-month FU. If not fused at 12 months, additional CT scans obtained at 24-month FU. If fused no additional CT scan at 24-month FU. |
| Faundez, 2009 | 82% at mean 33 months | Based on CT scans:  
* Solid radiological fusion*: bridging bone in both anterior (at least 30% endplate surface) and posterior columns or anterior column alone  
* Partial radiological fusion*: anterior column “probably fused” with any fusion status of posterior column  
* Inadequate radiological fusion: at least anterior column “not fused” or “probably not fused,” with any fusion status posteriorly  
* Indeterminate radiological fusion: indeterminate anterior fusion status with any fusion status posteriorly  
* Considered as adequate.  |
| Faundez, 2009 | 77% at mean 33 months | Based on CT scans:  
* Solid radiological fusion: bridging bone in both anterior (at least 30% endplate surface) and posterior columns or anterior column alone (considered adequate)  
* Partial radiological fusion: anterior column “probably fused” with any fusion status of posterior column (considered adequate)  
* Inadequate radiological fusion: at least anterior column “not fused” or “probably not fused,” with any fusion status posteriorly  
* Indeterminate radiological fusion: indeterminate anterior fusion status with any fusion status posteriorly  
* Grades according to Bridwell's anterior fusion grades  |
| Kim, 2011 | Bridwell grade I 73.2%  
Bridwell grade II 23.2% at a mean of 32.4 months | Based on CT scans:  
* Solid radiological fusion: bridging bone in both anterior (at least 30% endplate surface) and posterior columns or anterior column alone (considered adequate)  
* Partial radiological fusion: anterior column “probably fused” with any fusion status of posterior column (considered adequate)  
* Inadequate radiological fusion: at least anterior column “not fused” or “probably not fused,” with any fusion status posteriorly  
* Grades according to Bridwell's anterior fusion grades  |

(continued)
| Author, Year | Fusion Rate | Definition of Fusion |
|-------------|-------------|----------------------|
| Houten, 2006 | 100% at 11 months | 1. The absence of movement on flexion-extension X-ray films  
2. Presence of bone bridging between the graft and adjacent vertebral end-plates  
3. Lack of lucency around spinal instrumentation |
| Wetzel, 1993 | 58% at 27 months (plain X-ray) | Fusion was graded as solid according to visual inspection, if mature trabecular lines crossed all levels fused on plain X-rays. Additionally, X-rays were digitized and the amount of angular change (Cobb angle) and translational change between the cranial and caudal bodies included in the fusion were quantified. Fusion was felt to have occurred if, on serially digitized films, the Cobb angle changed less than 4°, and translation was less than 3 mm. Fusion was assessed by assessing sagittal change by digital roentgenographs. If less than 3 mm of change had occurred, this was taken to represent fusion. |
| Vamvanij, 1998 | 60% at a mean of 4.2 years | 1. Arthrodesis: absence of translucent line at the graft-vertebral end-plate interface, the presence of trabeculation crossing the interspace and less than 2° of motion on flexion-extension radiography.  
2. Functional arthrodesis: evidence of stability as there was less than 2° of motion on flexion-extension radiography and the presence of bridging bone anterior or posterior to the femoral graft. A translucent line was observed separating the vertebral end-plate from the bone graft on one or both sides however.  
3. Nonunion: Motion greater than 2° on flexion-extension analysis and the presence of a translucent line on plain X-rays at the vertebra-femoral graft interface. |
| Kumar, 1993 | On plain X-rays: 66%  
On dynamic X-ray: 22%  
Nonunion: 12% at 24 months | Presence of fusion was based on plain radiographs appearance; categorized into three groups  
1. Arthrodesis: absence of translucent line at the graft-vertebral end-plate interface, the presence of trabeculation crossing the interspace and less than 2° of motion on flexion-extension radiography.  
2. Functional arthrodesis: evidence of stability as there was less than 2° of motion on flexion-extension radiography and the presence of bridging bone anterior or posterior to the femoral graft. A translucent line was observed separating the vertebral end-plate from the bone graft on one or both sides however.  
3. Nonunion: Motion greater than 2° on flexion-extension analysis and the presence of a translucent line on plain X-rays at the vertebra-femoral graft interface. |
| PLF DBM, noninstrumented | Epstein NE, 2008 | 92.7% at 12 months  
2D-CT criteria for fusion included the demonstration of bony trabeculation/continuity of bone fragments between transverse processes, and/or facet fusion. Dynamic X-ray criteria for stability included <3 mm of translation, and <5 degrees of angulation. Patients were considered as demonstrating pseudarthrosis if they were “not fused” using either dynamic X-ray or 2D-CT examinations by either observer. |
| PLF DBM, instrumented | Epstein NE and JA, 2007 | 1-level fusions:  
On 2D-CT 92.6%  
On dynamic X-ray: 97.9%  
2-level fusions:  
On 2D-CT 91.1%  
On dynamic X-ray: 95.6% at up to 12 months until fusion was documented  
Fusion criteria on dynamic X-rays: <3 mm of translation and <5 degrees of angulation.  
2D-CT criteria for fusion: bony trabeculation and continuous fusion mass extending between adjacent transverse processes with a lack of screw loosening (absence of lucency surrounding the screws). |
| Kang, 2012 | DBM group: 86%  
ICBG group: 92% at 2 years | Fusion was defined as evidence of bilateral continuous bridging of trabeular bone as well as less than 3 mm of translation and less than 5° of angular motion on lateral flexion-extension radiographs. CT scans were assessed for continuous bone formation throughout the length of the fusion bed. Fusion was finally rated as 1. fused, 2. indeterminate, 3. not fused.  
For the final 24-month fusion status analysis, the subjects' radiological results were assessed as follows. Included in the final analysis were all subjects who reached the 12-month FU time point. If a subject had a radiograph and/or a CT scan that was assessed by the independent radiologist as “fused” at month 12 or at month 24 (when applicable), then the subject was classified as “fused” in the final analysis. If all the radiographs or CT scans obtained at months 12 and 24 were assessed as “not fused” and/or “indeterminate,” then the subject was classified as “not fused” in the final analysis.  
Radiographical: preoperatively and immediately after surgery and at 6 weeks, 3, 6, 12, and 24 months postoperatively. Flexion-extension radiographs and computed tomographic (CT) scans (high-resolution axial, sagittal, and coronal reformating) were obtained at 12-month FU. If not fused at 12 months, additional CT scans obtained at 24-month FU  
If fused no additional CT scan at 24-month FU |

(continued)
Table 2. (continued)

| Author, Year | Fusion Rate | Definition of Fusion |
|--------------|-------------|----------------------|
| **PLF/PLIF DBM, instrumented** | | |
| Sassard, 2000 | 60% at final FU (24-month radiographs used for final analysis, earlier radiographs used for imputation in case of missing value) | The bone graft mass was judged to be fused if there was uninterrupted bone bridging the transverse processes on at least one side of the fusion mass with no identifiable breaks, clefts, or areas of marked focal bone resorption. Definitive pseudoarthroses and fusion masses with marked bone resorption were judged as not fused. |
| **TLIF DBM, instrumented** | | |
| Park, 2011 | Grade 1: 50%  
Grade 2: 27.3%  
Grade 3: 3%  
Grade 4: 19.7% at 2 years | According to Burkus JK, Foley KT, Haid R, LeHuec JC. Surgical interbody research group—radiographic assessment of interbody fusion devices: fusion criteria for anterior lumbar interbody surgery. *Neurosurg Focus*. 2001;10:E1.  
On flexion/extension lateral radiographs: No motion (acceptable intraobserver measurement error was 3° angular motion or 3 mm of translation)  
On CT scan: continuous bony bridge within/around the cage (incorporation of the grafted bone into the vertebral end plates)  
New bone formation adjacent to or within the cage and/or fused posterior facet joint (the opposite side of TLIF approach)  
On dynamic radiographs and/or CT scan: Lack of radiolucent lines around the graft and cage as well as absence of a lucent hollow around the pedicle screws  
Subdivision of fusion into four grades:  
Grade 1 (definitely solid): no motion on flexion-extension radiographs, continuous bony bridge within/around the cage, new bone formation adjacent to or within the cage, and/or fused posterior facet joint on CT scan  
Grade 2 (possibly solid): no motion on dynamic radiographs and continuous bony incorporation within/around the cage, without evidence of new bone formation adjacent to or within the cage or facet joint fusion  
Grade 3 (probably not solid): no motion excluding evidence of bony incorporation within/around the cage  
Grade 4 (definitely not solid): motion on dynamic radiographs with no evidence of bony bridge within/around the cage  
Standing anteroposterior, lateral, flexion, and extension radiographs of the lumbosacral spine were collected from preoperative and final postoperative visit for the fusion assessment. Postoperative CT scan was also obtained at the final visit.  
They considered the Grades 1 and 2 as a radiographic solid fusion and the Grades 3 and 4 as a nonunion. |
| **ALIF and PLIF with structural allograft and DBM, instrumented** | 100% at 24 months | Radiological loss of the allograft end-plates, the end of progression of subsidence, and the stabilization of clinical symptoms as measured by the Oswestry Disability Index and VAS. |

Abbreviations: PLF, posterior lumbar fusion; PLIF, posterior lumbar interbody fusion; ALIF, anterior lumbar interbody fusion; CT, computed tomography; TLIF, transforaminal lumbar interbody fusion.
Table 3. Availability of Power Calculation.

| Author, Year | Intervention | Fusion rate | Power Calculation or Sample Size Justification |
|--------------|--------------|-------------|-----------------------------------------------|
| PLF, structural allograft, instrumented and noninstrumented | Andersen, 2009 | PLF with fresh frozen allograft Instrumented and noninstrumented | Instrumented: 81% Noninstrumented: 68% at 12 and 24 months | No information provided on sample size determination/power |
| PLF, allograft chips, instrumented | Ploumis, 2010 | Instrumented PLF with allograft (freeze-dried cancellous chips) with local autograft | 93.7% at 24 months | No information provided on sample size determination/power |
| PLF, structural allograft, instrumented | Arnold, 2009 | PLF without cage but with instrumentation | 98% at 12 and 24 months | No information provided on sample size determination/power |
| Kakiuchi, 1998 | | I-level PLIF with pedicle screws, and hooks and rods, with or without any internal fixation | 91.6% at 24 months | No information provided on sample size determination/power |
| AUF, posterior instrumentation, structural allograft, instrumented | Faundez, 2009 | ALIF combined with rods or transaminar facet screws (no cage) | 82% at 33 months | No information provided on sample size determination/power |
| Slosar, 2007 | | Instrumented ALIF with structural allograft (femoral ring) with additional chips in its middle | Grade 1: 82% Grade 2: 7% Grade 3/4: 11% at 24 months | No information provided on sample size determination/power |
| TJF, structural allograft, instrumented | Faundez, 2009 | TJF without cage but with instrumentation | 77% at 33 months | No information provided on sample size determination/power |
| Kim, 2011 | | TJF with Capston cage and instrumentation | Bridwell grade I: 73.2% Bridwell grade II: 23.2% at 32.4 months | No information provided on sample size determination/power |
| Houten, 2006 | | Instrumented TLIF with structural allograft and local autograft | 100% at 11 months | No information provided on sample size determination/power |
| AUF, structural allograft, noninstrumented | Wetzel, 1993 | ALIF with fibular allograft | 58% at 27 months (plain X-ray) 60% at 42 years | No information provided on sample size determination/power |
| Vamvanij, 1998 | | Allograft group: ALIF with fibula allograft Various ICBG control groups, (none standalone ICBG ALIF): ICBG PLF + pedicle screw ICBG PLF + facet screw ICBG ALIF w BAK | On plain X-rays: 66% On dynamic X-ray: 22% Nonunion: 12% at 24 months | No information provided on sample size determination/power |
| Kumar, 1993 | | ALIF with femoral strut allograft | | |
| PLF DBM, noninstrumented | Epstein NE, 2008 | PLF with DBM Osteofil without cage or instrumentation | 82.7% at 12 months | No information provided on sample size determination/power |
| PLF DBM, instrumented | Epstein NE and JA, 2007 | PLF with DBM Osteofil without cage but with instrumentation | One-level fusion: On 2D-CT 92.6% On dynamic X-ray: 97.9% Two-level fusion: On 2D-CT: 91.1% On dynamic X-ray: 95.6% at up to 12 months until fusion was documented | No information provided on sample size determination/power |

(continued)
| Author, Year | Intervention | Fusion rate | Power Calculation or Sample Size Justification |
|--------------|--------------|-------------|-----------------------------------------------|
| Kang, 2012   | instrumented PLF: DBM Grafton combined w/ local autograft vs ICBG | DBM group: 24 (86%) ICBG group: 12 (92%) at 2 years | No information provided on sample size determination/power |
| Sassard, 2000| PLIF/PLIF DBM, instrumented PLIF with DBM Grafton without cage but with instrumentation | DBM: 60% Control: 56% at final FU (24-month radiographs used for final analysis, earlier radiographs used for imputation in case of missing value) | No information provided on sample size determination/power |
| Park, 2011   | Instrumented TLIF with DBM (OsteofilRT) + local autograft | Grade 1: 50% Grade 2: 27.3% Grade 3: 3% Grade 4: 19.7% at 2 years | No information provided on sample size determination/power |
| Vaidya, 2007 | Instrumented ALIF and TLIF with structural allograft and DBM (no DBM brand information available) | 100% at 24 months | No information provided on sample size determination/power |

Abbreviations: PLF, posterior lumbar fusion; PLIF, posterior lumbar interbody fusion; ALIF, anterior lumbar interbody fusion; CT, computed tomography; TLIF, transforaminal lumbar interbody fusion.
33 to 68 patients and there was no control group. Fusion rates were 73.2% at 32.4 months and 100% at 11 months. Both studies reported improvements in the clinical outcomes assessed by Oswestry Disability Index (ODI), Visual Analogue Scale, or Prolo Scale.

**Demineralized Bone Matrix**

Six studies on DBM, 1 noninstrumented and 5 instrumented, were included in this review. Five (4 prospective and 1 retrospective) studies looked at DBM in posterior fusion, and one prospective study utilized DBM for both anterior and posterior procedures. In the noninstrumented PLF study, 75 patients received lamina autograft and DBM paste at a 1:1 ratio (Osteoform, Medtronics Sofamor Danek, Memphis, TN). At 12 months, 82.7% of the patients were deemed to be fused and the authors reported an improvement in the SF-36 score at the 1- and 2-year follow-up. In 2 prospective studies patients underwent PLF with DBM and local graft. In the study done by Epstein et al, 95 patients underwent single- and 45 two-level PLF with lamina autograft and DBM paste in a 50:50 ratio (Osteoform, Medtronics Sofamor Danek). Fusion rates assessed on 2D computed tomography were 92.6% for 1-level and 91.1% for 2-level procedures up to 12 months postoperatively (Tables 2 and 3). When the fusion was assessed on dynamic X-rays, the rates were 97.9% for 1-level and 95.6% for 2-level procedures. Kang and coworkers enrolled 46 patients randomly assigned to Grafton DBM Matrix (Medtronics, Memphis, TN) with local bone (30 patients) or ICBG (16 patients). At the 2-year follow-up, fusion rates of the DBM and ICBG groups were similar (86% vs 92%) along with the ODI and SF-36 score.

Three studies, 2 prospective and 1 retrospective, utilized a combination of DBM and autograft in PLF/PLIF, TLIF, or ALIF procedures. In a prospective case-control study, 56 patients underwent PLF or PLF/PLIF with Grafton DBM and local autograft, and 52 patients received ICBG. At 24 months, the results showed a 60% fusion rate in the DBM and a 56% fusion rate in the control group (Tables 2 and 3). However, this difference was not statistically significant. On the other hand, 100% fusion rates and minimal graft subsidence were reported by Vaidya et al, where patients underwent either ALIF (11) or TLIF (18) procedures with DBM and allograft. In a retrospective study, 66 patients underwent TLIF with a combination of DBM paste (Osteoform RT DBM paste; Regeneration Technologies Inc, Alachua, FL) and local autograft. At the 2-year follow-up, solid fusion was achieved in 77% of the patients; however, there were no significant differences in the clinical outcomes between patients with solid fusion and nonunion (Tables 2 and 3).

**Outcome Assessment**

In the majority of studies, the fusion assessment was performed by an independent or blinded observer. The definition of fusion varied between the studies, with no studies having the same fusion assessment protocol (Table 2). When analyzing the individual fusion definitions in relation to the achieved fusion rates, there were no discrepancies between the fusion percentage and the assessment stringency (Table 2).

**Lost to Follow-up**

In general, the rates of lost to follow-up were quite variable. Eight studies that documented radiological and clinical outcomes at various time points did not make any statements with regards to “lost to follow-up.” On the other hand, in the studies done by Kim et al and Houten et al, all of the patients had complete follow-ups for both radiological and clinical outcomes. Andersen et al reported clinical outcomes after a mean of 4.3 years and radiological outcomes up to 24 months. The follow-up rate in this study was 79%. This was the sole study that provided information on why patients were lost to follow-up and also analyzed the characteristics of patients included in the follow-up versus those lost to follow-up. In the studies conducted by Arnold et al and Sassard et al, the number of patients available for follow-up decreased from 12 to 24 months, from 83% to 54% and from 81% to 76%, respectively. Similar results for the clinical outcomes were observed in a study conducting by Kang et al. In the study done by Faundez and coworkers, radiological data was available for 59% of the ALIF and 54% of TLIF patients at 33 months, and the clinical follow-up rate was 64%. Slosar and coworkers followed-up patients up to 24 months for both radiological and clinical outcomes, and only 3 patients dropped over the 24-month time period.

**Conflict of Interest Declaration**

In 7 of the 17 articles, no conflict of interest statements was provided. Six studies were funded by the industry, and in 2 publications, some authors declared a consultancy role for the manufacturer of the used allograft.

**Discussion**

The purpose of this review was to determine the fusion efficacy of allograft and DBM in lumbar instrumented and noninstrumented fusion procedures for degenerative lumbar disorders. Seventeen studies met the inclusion criteria. However, a large variation in fusion rates, a lack of control group, and follow-up...
time prevented any significant conclusions. There were no obvious differences between allograft and DBM with regard to instrumented fusion procedures. For the allograft, the fusion rates were between 58% and 68% for noninstrumented lumbar fusions,42,47,49,50 and between 73% and 100% for instrumented fusions with and without additional local autograft.42,46,48,51,52 Regarding DBM, one study reported fusion rates of 82.7% for noninstrumented fusion,53 with the remaining studies reporting between 60% and 100% for instrumented procedures with or without autograft.

Autograft is the only graft material that has all 3 characteristics of the ideal graft: osteoconductivity, osteogenecity, and osteoinduction. Despite being considered the gold standard, a wide range of fusion rates has been reported in the literature. The use of autograft in instrumented lumbar fusion procedures has led to fusion rates between 54% and 99%,7-18,29 and for noninstrumented fusion between 30% and 100%.10,11,58-64

Based on those findings, allograft and DBM use had fusion ranges that overlap with autograft fusion rate ranges. Those results are in line with the recommendations created by Fischer and coworkers using Guyatt criteria and focusing on non–bone morphogenetic protein graft materials.39 In their review, a 1B grade was given to allograft use in PLF and ALIF approaches, reflecting a strong recommendation with a clear benefit to most of the patients. For DBM, the grading was dependent on whether DBM was used as a substitute or extender. The authors gave a 1C grade for PLF and ALIF surgeries due to the lack of RCTs.

Although the allograft and DBM can provide comparable fusion rates, our review found a large variability between the studies. There are several reasons that may have contributed to the heterogeneity, including the variability in the surgical approaches used to achieve fusion. Surgical techniques have been a subject of previous research and some of the approaches have demonstrated a clear advantage over others. Future prospective longitudinal studies are needed to establish what approach and material are best for a patient.

The diversity in diagnosis as well as the number of surgical levels was high, leading to too many confounding variables. Studies on allograft included spinal stenosis, degenerative lumbar scoliosis, spondylolisthesis, disc herniation or prolapse, trauma, and several others.42-52 The number of fused levels varied between single- to 5-level fusion, sometimes within the same study. Similar to the allograft studies, diagnosis heterogeneity was seen in the studies focusing on DBM.9,53-57 Furthermore, most of the studies with DBM included patients with failed surgery or pseudarthrosis as part of their cohorts. If recorded, the number of fused levels ranged between 1 and 5 vertebra. Another limitation in all of the studies was the methodological weakness. Most of the studies were purely observational without a control group and included poorly defined and/or mixed indications, procedures, and implants. None of the publications provided a power analysis or sample size justification.

Although most of the studies described the protocol for fusion assessment, there was no consistency in the definition of fusion. The differences in the individual fusion definitions revealed that patients deemed as fused in one study would be assessed as partially or inadequately fused in another study (Table 2). Only in 4 studies fusion rates were assessed by multiple observers, surgeons, and/or radiologists13,53,56,57, however, blinded assessment was done in only 2 studies.43,53 None of the 17 studies included in this review reported intra- or interobserver kappa values on fusion assessment reliability.

Aside from the surgical and clinical inconsistencies, the DBM preparation techniques are likely a strong contributor to the differences in fusion rates. Different methods of processing and sterilization influence DBM osteoinductivity, which together with the type of carrier and donor’s variability contribute to the wide range in fusion rates.

**Conclusion**

Based on an analysis of 17 studies, this review found a large variation in the fusion rates, surgical approaches, lack of control groups, and follow-up time preventing any significant conclusions. No RCT comparing allograft or DBM to autograft as an adjunct to fusion met the eligibility criteria for this review. Well-designed RCTs employing standardized surgical techniques, addressing the clinical safety and efficacy of allograft and DBM compared to autograft in large, homogeneous patient populations, and a sufficient follow-up time are needed to unequivocally establish the usefulness and efficacy of these materials as an adjunct to fusion.

**Declaration of Conflicting Interests**

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Financial activities outside of submitted work: ZB-Xenco Medical (consultancy) and AO Spine (consultancy, past). IBP and ER—Nothing to disclose. HJM—Dr Meisel is a consultant (money paid to institution); Regenerate Life Sciences GmbH for Zyga, DiFusion (ongoing), Co.don (paid to Dr Meisel, past); royalties from Medtronic, Fehling Aesculap (past); owns stocks (money paid to institution): Regenerate Life Sciences GmbH in DiFusion. STY—Dr Yoon owns stock in Phygen, Alphatec, Meditech; royalties: Meditech Advisors, Stryker Spine (paid directly to institution/employer), grant from AOSpine (paid directly to institution/employer), research support from Biomet (research support given to AREF), nonfinancial research support from NuVasive and Medtronic. JAY—Royalties: NuVasive, Osprey Medical, Amedica, Integra; Stock ownership: Benvenue Medical, Paradigm Spine, Promethean Surgical Devices, Spinal Ventures, VertiFlex, Spincity, ISD, Providence Medical; Private investments: Amedica, VertiFlex, Benvenue, NuVasive; Consulting: Integra, NuVasive, Amedica, HealthTrust; Board of directors: Durango Orthopedic Associates (None); Research support (staff and/or materials): Globus Medical (paid directly to institution/employer), NuVasive (paid directly to institution/employer), VertiFlex (paid directly to institution/employer), Integra (paid directly to institution/employer). DSB—Consultant: Vallum; Royalties: Amedica, DePuy Synthes, Medtronic; Fellowship support: AOSpine (paid directly to institution). JCW—Royalties: Aesculap, Biomet, Amedica, Seapine, Synthes; Stock ownership: Fzioded; Private investments: Prometheus Spine, Paradigm Spine, Benevenue, NexGen, VertiFlex, Electrocore.
Surgitec, Expanding Orthopaedics, Osprey, Bone Biologics, Curative Biosciences, Pearldiver; Board of directors: North American Spine Society (Second Vice President), North American Spine Foundation (nonfinancial), Cervical Spine Research Society (travel expenses), AO Spine/AO Foundation (honorariums for board position); Fellowship support: AO Foundation (spine fellowship funding paid to institution).

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by AOSSpine and departmental funds. AOSSpine is a clinical division of the AO Foundation—an independent medically guided nonprofit organization. The AOSSpine Knowledge Forums are pathology focused working groups acting on behalf of AOSSpine in their domain of scientific expertise. Each forum consists of a steering committee of up to 10 international spine experts who meet on a regular basis to discuss research, assess the best evidence for current practices, and formulate clinical trials to advance spine care worldwide. Study support is provided directly through AOSSpine’s Research Department.

References
1. Andersson GBJ, Bouchard J, Bozic KJ, et al. The Burden of Musculoskeletal Diseases in the United States. Rosemont, IL: American Academy of Orthopaedic Surgeons; 2011.
2. Pannell WC, Savin DD, Scott TP, Wang JC, Daubs MD. Trends in the surgical treatment of lumbar spine disease in the United States. Spine J. 2015;15:1719-1727.
3. Weinstein JN, Lurie JD, Olson PR, Bronner KK, Fisher ES. United States’ trends and regional variations in lumbar spine surgery: 1992-2003. Spine (Phila Pa 1976). 2006;31:2707-2714.
4. Slosar PJ, Perkins RB, Snook D. Effects of cigarette smoking on the spine: a focused review. SpineLine. 2002;3(5):6-9.
5. Glassman SD, Anagnost SC, Parker A, Burke D, Johnson JR, Dimar JR. The effect of cigarette smoking and smoking cessation on spinal fusion. Spine (Phila Pa 1976). 2000;25:2608-2615.
6. McCunniff PT, Young ES, Ahmadinia K, Ahn UM, Ahn NU. Smoking is associated with increased blood loss and transfusion use after lumbar spinal surgery. Clin Orthop Relat Res. 2016;474:1019-1025. doi:10.1007/s11999-015-4650-x.
7. Dimar JR 2nd, Glassman SD, Burkus JK, Pryor PW, Hardacker JW, Carreon LY. Two-year fusion and clinical outcomes in 224 patients treated with a single-level instrumented posterior lateral fusion with iliac crest bone graft. Spine J. 2009;9:880-885.
8. Fischgrund JS, Mackay M, Herkowitz HN, Brower R, Montgomery DM, Kurz LT. 1997 Volvo Award winner in clinical studies. Degenerative lumbar spondylolisthesis with spinal stenosis: a prospective, randomized study comparing decompressive laminectomy and arthrodesis with and without spinal instrumentation. Spine (Phila Pa 1976). 1997;22:2807-2812.
9. Kang J, An H, Hilibrand A, Yoon ST, Kavanagh E, Boden S. Graft and local bone have comparable outcomes to iliac crest bone in instrumented single-level lumbar fusions. Spine (Phila Pa 1976). 2012;37:1083-1091.
10. Ohtori S, Koshi T, Yamashita M, et al. Single-level instrumented posterolateral fusion versus non-instrumented anterior interbody fusion for lumbar spondylolisthesis: a prospective study with a 2-year follow-up. J Orthop Sci. 2011;16:352-358.
11. Bridwell KH, Sedgwick TA, O’Brien MF, Lenke LG, Baldus C. The role of fusion and instrumentation in the treatment of degenerative spondylolisthesis with spinal stenosis. J Spinal Disord. 1993;6:461-472.
12. Fritzell P, Hägg O, Wessberg P, Nordwall A; Swedish Lumbar Spine Study Group. Chronic low back pain and fusion: a comparison of three surgical techniques: a prospective multicenter randomized study from the Swedish lumbar spine study group. Spine (Phila Pa 1976). 2002;27:1131-1141.
13. Moller H, Hedlund R. Instrumented and noninstrumented posterior lateral fusion in adult spondylolisthesis—a prospective randomized study: part 2. Spine (Phila Pa 1976). 2000;25:1716-1721.
14. Pavlov PW, Meijers H, van Limbeek J, et al. Good outcome and restoration of lordosis after anterior lumbar interbody fusion with additional posterior fixation. Spine (Phila Pa 1976). 2004;29:1893-1899.
15. Saraph V, Lerch C, Walochnik N, Bach CM, Krismer M, Wimmer C. Comparison of conventional versus minimally invasive extra-peritoneal approach for anterior lumbar interbody fusion. Eur Spine J. 2004;13:425-431.
16. Schizas C, Triantafyllopoulos D, Kosmopoulos V, Tziniaris N, Stafylas K. Posterolateral lumbar spine fusion using a novel demineralized bone matrix: a controlled case pilot study. Arch Orthop Trauma Surg. 2008;128:621-625.
17. Vaccaro AR, Stubbs HA, Block JE. Demineralized bone matrix composite grafting for posterolateral spinal fusion. Orthopedics. 2007;30:567-570.
18. Sengupta DK, Truumees E, Patel CK, et al. Outcome of local bone versus autogenous iliac crest bone graft in the instrumented posterolateral fusion of the lumbar spine. Spine (Phila Pa 1976). 2006;31:985-991.
19. Miyazaki M, Tsumura H, Wang JC, Alany A. An update on bone substitutes for spinal fusion. Eur Spine J. 2009;18:783-799.
20. Fernyhough JC, Schimandle JJ, Weigel MC, Edwards CC, Levine AM. Chronic donor site pain complicating bone graft harvesting from the posterior iliac crest for spinal fusion. Spine (Phila Pa 1976). 1992;17:1474-1480.
21. Aghdasi B, Montgomery SR, Daubs MD, Wang JC. A review of demineralized bone matrices for spinal fusion: the evidence for efficacy. Surgeon. 2013;11:39-48.
22. Mroz TE, Joyce MJ, Lieberman IH, Steinmetz MP, Benzel EC, Wang JC. The use of allograft bone in spine surgery: is it safe? Spine J. 2009;9:303-308.
23. Salih E, Wang J, Mah J, Fluckiger R. Natural variation in the extent of phosphorylation of bone phosphoproteins as a function of in vivo new bone formation induced by demineralized bone matrix in soft tissue and bony environments. Biochem J. 2002;364(Pt 2):465-474.
24. Bae H, Zhao L, Zhu D, Kanim LE, Wang JC, Delamarter RB. Variability across ten production lots of a single demineralized bone matrix product. J Bone Joint Surg Am. 2010;92:427-435.
25. An HS, Lynch K, Toth J. Prospective comparison of autograft vs. allograft for adult posterolateral lumbar spine fusion: differences
among freeze-dried, frozen, and mixed grafts. J Spinal Disord. 1995;8:131-135.
26. Gibson S, McLeod I, Wardlaw D, Urbaniak S. Allograft versus autograft in instrumented posterolateral lumbar spinal fusion: a randomized control trial. Spine (Phila Pa 1976). 2002;27:1599-1603.
27. Knapp DR Jr, Jones ET, Blanco JS, Flynn JC, Price CT. Allograft bone in spinal fusion for adolescent idiopathic scoliosis. J Spinal Disord Tech. 2005;18(suppl):S73-S76.
28. Jones KC, Andrish J, Kuivila T, Gurd A. Radiographic outcomes using freeze-dried cancellous allograft bone for posterior spinal fusion in pediatric idiopathic scoliosis. J Pediatr Orthop. 2002;22:285-289.
29. Cammisa FP Jr, Lowery G, Garfin SR, et al. Two-year fusion rate equivalency between Grafton DBM gel and autograft in postero-lateral spine fusion: a prospective controlled trial employing a side-by-side comparison in the same patient. Spine (Phila Pa 1976). 2004;29:660-666.
30. Cabraja M, Kroppenstedt S. Bone grafting and substitutes in spine surgery. J Neurosurg Sci. 2012;56:87-95.
31. Chau AM, Mobbs RJ. Bone graft substitutes in anterior cervical discectomy and fusion. Eur Spine J. 2009;18:449-464.
32. Drosos GI, Kazakos KI, Kouzoumpasis P, Verettas DA. Safety and efficacy of commercially available demineralised bone matrix preparations: a critical review of clinical studies. Injury. 2007;38(suppl 4):S13-S21.
33. Epstein NE. Efficacy of different bone volume expanders for augmenting lumbar fusions. Surg Neurol. 2008;69:16-19.
34. Glassman SD, Howard JM, Sweet A, Carreon LY. Complications and concerns with osteobiologics for spine fusion in clinical practice. Spine (Phila Pa 1976). 2010;35:1621-1628.
35. Park JJ, Hershman SH, Kim YH. Updates in the use of bone grafts in the lumbar spine. Bull Hosp Jt Dis (2013). 2013;71:39-48.
36. Rihm JA, Kirkpatrick K, Albert TJ. Graft options in posterolateral and posterior interbody lumbar fusion. Spine (Phila Pa 1976). 2010;35:1629-1639.
37. Abdullah KG, Steinmetz MP, Benzal EC, Mroz TE. The state of lumbar fusion extenders. Spine (Phila Pa 1976). 2011;36:E1328-E1334.
38. Aggarwal R, Williams K, Umscheid CA, Welch WC. osteoinductive bone graft substitutes for lumbar fusion: a systematic review. J Neurosurg Spine. 2009;11:729-740.
39. Fischer CR, Cassilly R, Cantor W, Edusei E, Hammouri Q, Errico T. A systematic review of comparative studies on bone graft alternatives for common spine fusion procedures. Eur Spine J. 2013;22:1432-1435.
40. Khashan M, Inoue S, Berven SH. Cell based therapies as compared to autologous bone grafts for spinal arthrodesis. Spine (Phila Pa 1976). 2013;38:1885-1891.
41. Mobbs RJ, Chung M, Rao PJ. Bone graft substitutes for anterior lumbar interbody fusion. Orthop Surg. 2013;5:77-85.
42. Andersen T, Christensen FB, Niedermann B, et al. Impact of instrumentation in lumbar spinal fusion in elderly patients: 71 patients followed for 2-7 years. Acta Orthop. 2009;80:445-450.
43. Ploumis A, Albert TJ, Brown Z, Mehdod AA, Transfeldt EE. Healos graft carrier with bone marrow aspirate instead of allograft as adjunct to local autograft for posterolateral fusion in degenerative lumbar scoliosis: a minimum 2-year follow-up study. J Neurosurg Spine. 2010;13:211-215.
44. Arnold PM, Robbins S, Paullus F, Faust S, Holt R, McGuire R. Clinical outcomes of lumbar degenerative disc disease treated with posterior lumbar interbody fusion allograft spacer: a prospective, multicenter trial with 2-year follow-up. Am J Orthop (Belle Mead NJ). 2009;38:E115-E122.
45. Kakiuchi M, Ono K. Defatted, gas-sterilised cortical bone allograft for posterior lumbar interbody vertebral fusion. Int Orthop. 1998;22:69-76.
46. Faundez AA, Schwender JD, Safriel Y, et al. Clinical and radiological outcome of anterior-posterior fusion versus transformaminal lumbar interbody fusion for symptomatic disc degeneration: a retrospective comparative study of 133 patients. Eur Spine J. 2009;18:203-211.
47. Kumar A, Kozak JA, Doherty BJ, Dickson JL. Interspace distraction and graft subsidence after anterior lumbar fusion with femoral strut allograft. Spine (Phila Pa 1976). 1993;18:2393-2400.
48. Slosar PJ, Josey R, Reynolds J. Accelerating lumbar fusions by combining rhBMP-2 with allograft bone: a prospective analysis of interbody fusion rates and clinical outcomes. Spine J. 2007;7:301-307.
49. Wetzel FT, Hoffman MA, Arcieri RR. Freeze-dried fibular allograft in anterior spinal surgery: cervical and lumbar applications. Yale J Biol Med. 1993;66:263-275.
50. Vamvanij V, Fredrickson BE, Thorpe JM, Stadnick ME, Yuan HA. Surgical treatment of internal disc disruption: an outcome study of four fusion techniques. J Spinal Disord. 1998;11:375-382.
51. Kim MC, Chung HT, Kim DJ, Kim SH, Jeon SH. The clinical and radiological outcomes of minimally invasive transformaminal lumbar interbody single level fusion. Asian Spine J. 2011;5:111-116.
52. Houten JK, Post NH, Dryer JW, Errico TJ. Clinical and radiographically/neuroimaging documented outcome in transformaminal lumbar interbody fusion. Neurosurg Focus. 2006;20:E8.
53. Epstein NE. Fusion rates and SF-36 outcomes after multilevel laminectomy and noninstrumented lumbar fusions in a predominantly geriatric population. J Spinal Disord Tech. 2008;21:159-164.
54. Epstein NE, Epstein JA. SF-36 outcomes and fusion rates after multilevel laminectomies and 1- and 2-level instrumented posterior-lateral fusions using lamina autograft and demineralized bone matrix. J Spinal Disord Tech. 2007;20:139-145.
55. Sassard WR, Eidman DK, Gray PM, et al. Augmenting local bone with Grafton demineralized bone matrix for posterolateral lumbar spine fusion: avoiding second site autologous bone harvest. Orthopedics. 2000;23:1059-1064.
56. Park Y, Ha JW, Lee YT, Sung NY. The effect of a radio-guided solid fusion on clinical outcomes after minimally invasive transformaminal lumbar interbody fusion. Spine J. 2011;11:205-212.
fusion but early subsidence. *J Bone Joint Surg Br.* 2007;89:342-345.

58. Burkus JK, Heim SE, Gornet MF, Zdeblick TA. Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device. *J Spinal Disord Tech.* 2003;16:113-122.

59. Cheung KM, Zhang YG, Lu DS, Luk KD, Leong JC. Reduction of disc space distraction after anterior lumbar interbody fusion with autologous iliac crest graft. *Spine (Phila Pa 1976).* 2003;28:1385-1389.

60. Greenough CG, Taylor LJ, Fraser RD. Anterior lumbar fusion: results, assessment techniques and prognostic factors. *Eur Spine J.* 1994;3:225-230.

61. Ishihara H, Osada R, Kanamori M, et al. Minimum 10-year follow-up study of anterior lumbar interbody fusion for isthmic spondylolisthesis. *J Spinal Disord.* 2001;14:91-99.

62. Motosuneya T, Asazuma T, Nobuta M, Masuoka K, Ichimura S, Fujikawa K. Anterior lumbar interbody fusion: changes in area of the dural tube, disc height, and prevalence of cauda equina adhesion in magnetic resonance images. *J Spinal Disord Tech.* 2005;18:18-22.

63. Newman MH, Grinstead GL. Anterior lumbar interbody fusion for internal disc disruption. *Spine (Phila Pa 1976).* 1992;17:831-833.

64. Tiusanen H, Seitsalo S, Osterman K, Soini J. Anterior interbody lumbar fusion in severe low back pain. *Clin Orthop Relat Res.* 1996;(324):153-163.